The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema

To evaluate the effect of systemic factors on best-corrected visual acuity (BCVA) achieved with ranibizumab (Lucentis; Genentech, Inc, South San Francisco, CA) for treatment of diabetic macular edema (DME) in the RIDE and RISE phase 3 studies. Exploratory, post hoc analysis of 2 randomized, double-m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Ophthalmology (Rochester, Minn.) Jg. 123; H. 7; S. 1581 - 1587
Hauptverfasser:	Singh, Rishi P, Habbu, Karishma, Ehlers, Justis P, Lansang, M Cecilia, Hill, Lauren, Stoilov, Ivaylo
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.07.2016
Schlagworte:	Adult Aged Angiogenesis Inhibitors - therapeutic use Biomarkers - blood Blood Glucose - analysis Blood Pressure - physiology Diabetic Retinopathy - blood Diabetic Retinopathy - drug therapy Diabetic Retinopathy - physiopathology Double-Blind Method Female Glycated Hemoglobin A - analysis Humans Intravitreal Injections Macular Edema - blood Macular Edema - drug therapy Macular Edema - physiopathology Male Middle Aged Ranibizumab - therapeutic use Visual Acuity - physiology
ISSN:	1549-4713
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!